Alison Ritter
Alison Ritter
Drug Policy Modelling Program, UNSW Australia
Verified email at
Cited by
Cited by
A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs
A Ritter, J Cameron
Drug and alcohol review 25 (6), 611-624, 2006
The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS)
J Ross, M Teesson, S Darke, M Lynskey, R Ali, A Ritter, R Cooke
Drug and alcohol review 24 (5), 411-418, 2005
How do drug policy makers access research evidence?
A Ritter
International Journal of Drug Policy 20 (1), 70-75, 2009
One year outcomes for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS)
M Teesson, J Ross, S Darke, M Lynskey, R Ali, A Ritter, R Cooke
Drug and alcohol dependence 83 (2), 174-180, 2006
Studying illicit drug markets: Disciplinary contributions
A Ritter
International Journal of Drug Policy 17 (6), 453-463, 2006
Serious adverse events in the Australian national evaluation of pharmacotherapies for opioid dependence (NEPOD)
E Digiusto, A Shakeshaft, A Ritter, S O'Brien, RP Mattick, ...
Addiction 99 (4), 450-460, 2004
LAAM maintenance vs methadone maintenance for heroin dependence
NC Clark, N Lintzeris, A Gijsbers, G Whelan, A Dunlop, A Ritter, WW Ling
Cochrane Database of Systematic Reviews, 2002
The reliability and internal validity of the Wisconsin Card Sorting Test
SC Bowden, KS Fowler, RC Bell, G Whelan, CC Clifford, AJ Ritter, ...
Neuropsychological Rehabilitation 8 (3), 243-254, 1998
Producing the ‘problem of drugs’: A cross national-comparison of ‘recovery’discourse in two Australian and British reports
K Lancaster, K Duke, A Ritter
International Journal of Drug Policy 26 (7), 617-625, 2015
Examining the construction and representation of drugs as a policy problem in Australia's National Drug Strategy documents 1985–2010
K Lancaster, A Ritter
International Journal of Drug Policy 25 (1), 81-87, 2014
A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting
AH Harris, E Gospodarevskaya, AJ Ritter
Pharmacoeconomics 23 (1), 77-91, 2005
Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose
AJ Ritter
Australian & New Zealand Journal of Psychiatry 36 (2), 224-228, 2002
The ethics of paying drug users who participate in research: A review and practical recommendations
CL Fry, W Hall, A Ritter, R Jenkinson
Journal of Empirical Research on Human Research Ethics 1 (4), 21-35, 2006
Paying research participants: a study of current practices in Australia
CL Fry, A Ritter, S Baldwin, KJ Bowen, P Gardiner, T Holt, R Jenkinson, ...
Journal of medical ethics 31 (9), 542-547, 2005
The relationship between take‐away methadone policies and methadone diversion
A Ritter, R Di Natale
Drug and Alcohol Review 24 (4), 347-352, 2005
The ethics of reimbursing injecting drug users for public health research interviews: what price are we prepared to pay?
AJ Ritter, A Swan, CL Fry
[Sl]: Elsevier,, 2003
The influence of the therapeutic relationship in treatment for alcohol dependency
A Ritter, S Bowden, T Murray, P Ross, J Greeley, J Pead
Drug and alcohol review 21 (3), 261-268, 2002
Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial
N Lintzeris, A Ritter, M Panjari, N Clark, J Kutin, G Bammer
The American journal on addictions 13 (S1), S29-S41, 2004
Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions
CL Breen, SJ Harris, N Lintzeris, RP Mattick, L Hawken, J Bell, AJ Ritter, ...
Drug and alcohol dependence 71 (1), 49-55, 2003
Naltrexone in the treatment of heroin dependence: a literature review
TK Tucker, AJ Ritter
Drug and Alcohol Review 19 (1), 73-82, 2000
The system can't perform the operation now. Try again later.
Articles 1–20